back to US directory
us clinical guidance

Allergic and nonallergic rhinitis

US allergy-practice guidance for rhinitis classification, targeted testing, intranasal therapy, comorbidity and escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults and children with allergic rhinitis, nonallergic rhinitis or mixed rhinitis. This page addresses upper-airway symptoms and common ambulatory management; anaphylaxis, acute bacterial sinusitis, chronic rhinosinusitis with polyps and severe asthma have separate diagnostic and treatment pathways.
sources for this section:Rhinitis 2020

The Bottom Line

  • Classify the symptom pattern and distinguish allergic rhinitis from nonallergic phenotypes and structural, infectious, medication-related or cerebrospinal-fluid mimics before escalating treatment.
  • Use history-linked aeroallergen skin testing or serum specific IgE when confirmation will change avoidance, immunotherapy or diagnostic decisions; broad untargeted panels and food-allergy testing do not diagnose routine rhinitis.
  • For persistent allergic rhinitis, an intranasal corticosteroid is the preferred single controller; demonstrate regular, correctly directed administration and allow adequate time before judging failure.
  • An intranasal corticosteroid plus an intranasal antihistamine can provide additional benefit when monotherapy is insufficient, and intranasal antihistamine is also an option in nonallergic rhinitis.
  • Reserve montelukast for allergic rhinitis when alternative therapies have provided inadequate response or are not tolerated, accounting for its current FDA boxed warning.
sources for this section:Rhinitis 2020

Practical clinical workflow

1
Characterize itching, sneezing, rhinorrhea, blockage, seasonality, triggers and eye symptoms; review occupational exposure, medicines, asthma, sleep, sinus symptoms and prior treatment technique.
2
Examine the nose and upper airway, looking for unilateral obstruction, bleeding, masses, polyps or clear unilateral drainage that changes the diagnostic pathway.
3
Begin allergen and irritant reduction that is feasible, saline if desired, and phenotype-matched intranasal treatment; teach spray direction away from the septum and discuss expected onset.
4
Review adherence, technique, epistaxis, symptom control and lower-airway disease before adding therapy; test selectively or refer when diagnosis or immunotherapy candidacy remains uncertain.
5
Consider allergen immunotherapy with an allergy specialist for confirmed clinically relevant sensitization and persistent symptoms, using the product-specific safety and asthma requirements.
sources for this section:Rhinitis 2020

Safety boundaries and escalation

  • Airway compromise, systemic allergic symptoms or rapidly progressive tongue or throat swelling follows the anaphylaxis emergency pathway rather than a rhinitis visit.
  • Unilateral obstruction or bleeding, facial or orbital complications, neurologic signs, recurrent severe epistaxis or suspected cerebrospinal-fluid leak requires urgent targeted assessment.
  • Avoid routine depot parenteral corticosteroid treatment for allergic rhinitis; systemic exposure can cause serious harm disproportionate to a usually controllable condition.
  • Check the current FDA montelukast boxed warning and discuss neuropsychiatric risk; confirm age, pregnancy, device and product labeling for every treatment.
sources for this section:Rhinitis 2020

Localization

Follow the AAAAI/ACAAI Joint Task Force practice parameter with current FDA labels and locally available immunotherapy products. US OTC status does not remove counseling or safety duties.
sources for this section:Rhinitis 2020

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Joint Task Force on Practice Parameters of the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma & ImmunologyRhinitis 2020: A practice parameter updateDOI 10.1016/j.jaci.2020.07.007 路 published 2020-07-22 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.